- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TURN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.10. | WBB Securities stuft Turn Therapeutics auf "Hold" hoch - Kursziel 10,00 $ | 1 | Investing.com Deutsch | ||
| 23.10. | WBB Securities upgrades Turn Therapeutics stock rating to hold | 2 | Investing.com | ||
| 07.10. | Turn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.09. | Lucid Capital Markets initiates Turn Therapeutics stock with buy rating | 5 | Investing.com | ||
| 23.09. | Turn Therapeutics auf dem Stifel Forum: Juckreiz-Score als Schlüssel für Studiendesign | 2 | Investing.com Deutsch | ||
| 09.09. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.08. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Turn Therapeutics Inc. GAAP EPS of -$0.20 | 3 | Seeking Alpha | ||
| 12.08. | Turn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.07. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | Turn Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Turn Therapeutics: Positive Studiendaten zu Ekzem-Medikament treiben Aktie an | 3 | Investing.com Deutsch | ||
| 01.06. | Turn Therapeutics reports interim phase 2 data for eczema drug | 2 | Investing.com | ||
| 27.05. | Turn Therapeutics publishes GX-03 dermatitis study results | 1 | Investing.com | ||
| 27.05. | Turn Therapeutics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.05. | Turn Therapeutics Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 18.05. | Turn Therapeutics appoints former FDA chief Stephen Hahn | 3 | Investing.com | ||
| 11.05. | Turn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Turn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | 340 | GlobeNewswire (Europe) | Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 16,688 | -1,96 % | Viatris Inc.: Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. | PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary... ► Artikel lesen | |
| SYNBIOTIC | 0,150 | -27,36 % | SYNBIOTIC SE: Zuvor aufgezeigte Risiken haben sich materialisiert; Rating und Kursziel under review | SYNBIOTIC hat angekündigt, einen Insolvenzantrag zu stellen, nachdem es dem Unternehmen angesichts anhaltend schwieriger Marktbedingungen nicht gelungen ist, eine ausreichende Finanzierung sicherzustellen.... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,809 | -4,37 % | Organigram Global Inc.: Organigram Global treibt die Integration der Sanity Group unter einer einheitlichen globalen Betriebsstruktur voran | Führung, operatives Geschäft und Marktentwicklung werden über eine globale Plattform aufeinander abgestimmt, die Kanada mit Deutschland und anderen wichtigen internationalen Märkten verbindet
Die... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 4,540 | -1,50 % | Tonix Pharmaceuticals ernennt George Lederman zum Executive Vice President | ||
| ORAMED PHARMACEUTICALS | 3,575 | -2,46 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 7,880 | -9,01 % | Sellas Life Sciences Group: 8-K nach Preclinical-Daten - was hinter dem Schub steckt | ||
| OPKO HEALTH | 1,480 | +0,68 % | OPKO Health, Inc.: OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026 | ||
| XORTX THERAPEUTICS | 0,913 | -1,14 % | XORTX Therapeutics Inc.: XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO, Targeting USD$700M+ U.S. Gout Market Opportunity | CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative... ► Artikel lesen | |
| SOLIGENIX | 0,367 | +2,34 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| OPUS GENETICS | 3,300 | +0,61 % | Opus Genetics appoints chief scientific officer, operations head | ||
| TALPHERA | 0,915 | -3,17 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,232 | -1,38 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| SCYNEXIS | 3,570 | +6,41 % | SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | • SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated • Phase 2 proof-of-concept study in patients with ADPKD remains... ► Artikel lesen | |
| PROTHENA | 7,560 | -0,50 % | Prothena Corporation plc: Prothena to Report Third Quarter 2026 Financial Results on November 5 | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 3,205 | -0,31 % | Wave Life Sciences, Inc. - 10-Q, Quarterly Report |
Das Unternehmen TURN THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,730 (-6,99 %) liegt der Kurs bei 9,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TURN THERAPEUTICS INC finden Sie auf Wallstreet Online.